DAX20.642 -5,0%ESt504.878 -4,6%Top 10 Crypto11,23 +2,3%Dow38.315 -5,5%Nas15.588 -5,8%Bitcoin76.104 -0,2%Euro1,0961 ±-0,0%Öl66,06 -5,4%Gold3.038 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 Apple 865985 Amazon 906866 Allianz 840400 Mercedes-Benz Group (ex Daimler) 710000 RENK RENK73 Lufthansa 823212 Infineon 623100 Microsoft 870747 BASF BASF11 Deutsche Bank 514000 Volkswagen (VW) vz. 766403 Nike 866993
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Zölle: China schlägt zurück -- DAX geht massiv tiefer ins Wochenende -- Wall Street stürzt letztlich ab -- Aktien von Rheinmetall, RENK & HENSOLDT im Minus -- Novo Nordisk, Apple im Fokus
Top News
Goldpreis, Ölpreis & Co. - Das waren die Tops und Flops der Rohstoffe in KW 14 Goldpreis, Ölpreis & Co. - Das waren die Tops und Flops der Rohstoffe in KW 14
EU-Neuwagenmarkt rückläufig - E-Autos trotz Tesla-Schwäche auf Erfolgskurs EU-Neuwagenmarkt rückläufig - E-Autos trotz Tesla-Schwäche auf Erfolgskurs
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Syndax Pharmaceuticals Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
11,00 EUR -0,20 EUR -1,79 %
FSE
11,24 USD -1,22 USD -9,76 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.883,13 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2AFL6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS87164F1057

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSNDX

Syndax Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
PR NewswireSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
PR NewswireSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
PR NewswireSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
PR NewswireSyndax Announces Appointment of Steven Closter as Chief Commercial Officer
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences
PR NewswireSyndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireSyndax Highlights Recent Updates and Anticipated 2024 Milestones
PR NewswireSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
PR NewswireSyndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
PR NewswireSyndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting
PR NewswireSyndax Announces Participation at Stifel Healthcare Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting
PR NewswireSyndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting
PR NewswireSyndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023
PR NewswireSyndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
PR NewswireSyndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis
PR NewswireSyndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation at the Citi 18th Annual BioPharma Conference
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
PR NewswireSyndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023
PR NewswireSyndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireSyndax Announces Participation at Two Upcoming Investor Conferences
PR NewswireSyndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
Wer­bung

Syndax Pharmaceuticals News

Syndax Pharmaceuticals News: auf dieser Seite finden Sie alle Syndax Pharmaceuticals News und Nachrichten zur Syndax Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Syndax Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Syndax Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.